Clinical Trial Update: Immune Cell Subsets in SLE Patients Treated with Telitacicept [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating immune cell subsets in systemic lupus erythematosus patients treated with Telitacicept; the study is currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Telitacicept

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Systemic Lupus Erythematosus (SLE) | Phase 4 | Status: ACTIVE_NOT_RECRUITING